

VIA FACSIMILE TRANSMISSION

Date of Deposit: January 16, 2002

Attorney Docket No. 22058-521

#13/B
Dmt
1-18-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Keith et al.

SERIAL NUMBER: 09/521,696

EXAMINER: J. Seharaseyon

FILING DATE: March 9, 2000

ART UNIT: 1647

FOR: Use of Interleukin-11 To Prevent Immune-Mediated Cytotoxicity

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL RESPONSE

Further to the Amendment submitted November 26, 2001 for the above-referenced application, applicants submit herewith a clean copy of the claim amendments and new claims added.

B1
sub C17
1. (Amended) A method of preventing complement-mediated cytotoxicity in a mammal which comprises
C
identifying a mammal at risk of developing complement-mediated cytotoxicity; and
administering to said mammal, prior to tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 prevents complement-mediated cytotoxicity in said mammal

B2
sub C27
3. (Amended) A method of ameliorating complement-mediated cytotoxicity in a mammal which comprises
C
identifying a mammal at risk of developing complement-mediated cytotoxicity; and